Celltrion Pharm Inc (068760) - Total Liabilities
Based on the latest financial reports, Celltrion Pharm Inc (068760) has total liabilities worth ₩319.38 Billion KRW (≈ $216.44 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Celltrion Pharm Inc cash conversion from operations to assess how effectively this company generates cash.
Celltrion Pharm Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Celltrion Pharm Inc's total liabilities have evolved over time, based on quarterly financial data. Check Celltrion Pharm Inc (068760) asset resilience to evaluate the company's liquid asset resilience ratio.
Celltrion Pharm Inc Competitors by Total Liabilities
The table below lists competitors of Celltrion Pharm Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bukit Uluwatu Villa Tbk
JK:BUVA
|
Indonesia | Rp584.34 Billion |
|
Zhuzhou Times New Material Technology Co Ltd
SHG:600458
|
China | CN¥18.32 Billion |
|
Chinese Universe Publishing And Media Co Ltd
SHG:600373
|
China | CN¥10.15 Billion |
|
Merchants Bancorp
NASDAQ:MBIN
|
USA | $17.13 Billion |
|
Arcelik AS
IS:ARCLK
|
Turkey | TL467.63 Billion |
|
Nexa Resources SA
NYSE:NEXA
|
USA | $3.92 Billion |
|
China Publishing & Media Hldg
SHG:601949
|
China | CN¥5.32 Billion |
|
Alembic Pharmaceuticals Limited
NSE:APLLTD
|
India | Rs30.81 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Celltrion Pharm Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Celltrion Pharm Inc (068760) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celltrion Pharm Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celltrion Pharm Inc (2011–2024)
The table below shows the annual total liabilities of Celltrion Pharm Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩272.54 Billion ≈ $184.70 Million |
+2.85% |
| 2023-12-31 | ₩264.98 Billion ≈ $179.57 Million |
+9.07% |
| 2022-12-31 | ₩242.94 Billion ≈ $164.64 Million |
-20.59% |
| 2021-12-31 | ₩305.92 Billion ≈ $207.31 Million |
+23.60% |
| 2020-12-31 | ₩247.51 Billion ≈ $167.74 Million |
+29.62% |
| 2019-12-31 | ₩190.95 Billion ≈ $129.40 Million |
+4.68% |
| 2018-12-31 | ₩182.41 Billion ≈ $123.62 Million |
+3.26% |
| 2017-12-31 | ₩176.65 Billion ≈ $119.71 Million |
+6.82% |
| 2016-12-31 | ₩165.37 Billion ≈ $112.07 Million |
-28.27% |
| 2015-12-31 | ₩230.54 Billion ≈ $156.23 Million |
+17.18% |
| 2014-12-31 | ₩196.74 Billion ≈ $133.33 Million |
+1.97% |
| 2013-12-31 | ₩192.94 Billion ≈ $130.75 Million |
+11.01% |
| 2012-12-31 | ₩173.80 Billion ≈ $117.78 Million |
+97.92% |
| 2011-12-31 | ₩87.81 Billion ≈ $59.51 Million |
-- |
About Celltrion Pharm Inc
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals a… Read more